^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mvasi (bevacizumab-awwb)

    i
    Other names: ABP 215, ABP-215, ABP215
    Company:
    AbbVie, Amgen, Daiichi Sankyo
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    10ms
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Recruiting, Amgen | Trial completion date: Apr 2031 --> Aug 2031 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    1year
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Recruiting, Amgen | Trial completion date: Jan 2031 --> Apr 2031 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    over1year
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    almost2years
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Amgen
    New P3 trial • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    2years
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Criterium, Inc. | N=43 --> 0 | Trial completion date: Jun 2028 --> Jan 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Jan 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    over2years
    Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb). (PubMed, Ther Adv Med Oncol)
    None of the EOIs resulted in death. In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.
    Journal • Real-world evidence • Real-world • Metastases
    |
    Mvasi (bevacizumab-awwb)
    over3years
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=43, Recruiting, Criterium, Inc. | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
    Enrollment open • Trial initiation date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    almost4years
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, Criterium, Inc.
    New P1/2 trial • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    4years
    A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101). (ASCO-GI 2022)
    Key regimens being explored in CRC include (1) Subprotocol A: Sotorasib + trametinib (MEK inhibitor) +/- panitumumab (EGFR inhibitor), (2) Subprotocol H: Sotorasib + panitumumab and sotorasib + panitumumab + FOLFIRI, and (3) Subprotocol M: Sotorasib + bevacizumab-awwb + FOLFIRI or FOLFOX. Contact Amgen Medical Information for more information: medinfo@amgen.com (NCT04185883). Abbreviations: EGFR = epidermal growth factor receptor; FOLFIRI = 5-fluorouracil + leucovorin + irinotecan; FOLFOX = 5-fluorouracil + leucovorin + oxaliplatin; MEK = mitogen-activated protein kinase.
    P1 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C
    |
    Avastin (bevacizumab) • Mekinist (trametinib) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • oxaliplatin • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    almost5years
    Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    over5years
    A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2; N=30; Recruiting; Sponsor: Elizabeth Buchbinder; Not yet recruiting --> Recruiting; Trial primary completion date: Sep 2020 --> Sep 2022
    Trial primary completion date • Enrollment open
    |
    ALB (Albumin)
    |
    PD-L1 negative • TILs
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb)